Trial Parameters
Brief Summary
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
Eligibility Criteria
Inclusion Criteria for CKD subjects: * CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit Inclusion Criteria for Healthy subjects: • eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function Exclusion Criteria: * Known intolerance or allergy to the diuretics * Current systemic chemotherapy for malignancy * Kidney transplant recipient * Use of calcineurin-inhibitors * Life expectancy \< 12 months * Current immunosuppressive treatment for glomerulonephritis * Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team * Hypokalemia or hyperkalemia (K+ \< 3.0mmol/L or K+ \> 5.5 mmol/L) at inclusion visit * Hypo- or hypernatremia (Na+ \< 130 mmol/L or Na+ \> 150mmol/L) at inclusion visit * Inherited tubulopathy as the cause of CKD * Autosomal dominant polycystic or tubulointerstitial kidney d